Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Hepatitis Health Center

Font Size

Longer-Acting Drug Approved for Hepatitis C


Last week, the FDA approved PEG-Intron, which is basically a longer-acting version of the interferon alpha Barb currently takes.

Part of what has her hopes up -- and the hopes of her fellow patients at the hepatitis clinic -- is that they've heard that the drug's manufacturer, Schering-Plough, is claiming that a combination of ribavirin and the new long-acting PEG-Intron is more likely to knock out the hepatitis C virus than the standard interferon regimen.

Studies have shown that only about 40% of patients taking the standard treatment will have a successful response, while the response rate seen in clinical trials of PEG-Intron and ribavirin range from 42-82%.

"The talk around the waiting room," Barb says, is that side effects may be about the same. But even if that's so, she says, the simplicity of once-a-week dosing should make life easier.

She may not get the chance to find out. The FDA has approved PEG-Intron only for use by itself, not in combination with other drugs -- and it hasn't even reached U.S. pharmacy shelves at this point.

In Munich, Josef says he hopes Barb gets a shot at the new drug. Josef is one of more than 1,500 patients who participated in a European trial of the long-acting drug in combination with ribavirin.

"When the study started, I had 2.5 million copies of the [hepatitis C] virus in my cells. That is hard to imagine, so much disease in one cell," Josef recalls.

Upon completing the trial, his viral load was down to 500 copies per cell, he says. "I think that is a response," Josef says.

Meanwhile, Barb continues to plan her life around the needle.

Today, it's late Sunday afternoon, and she's making preparations for a small group of friends and family who are coming over for a Super Bowl party. It's a good day to do it, she says, "because it's Sunday. I haven't had a shot since Friday. I guess you could say this is the very best day of the week for me. A good day for a party."

1 | 2

Today on WebMD

Hepatitus C virus
Types, symptoms and treatments.
liver illustration
Myths and facts about this essential organ.
woman eating apple
What you need to know.
doctor and patient
What causes it?
Hepatitis C Treatment
Syringes and graph illustration
liver illustration
passport, pills and vaccine
Scientist looking in microscope
Fatty Liver Disease
Digestive Diseases Liver Transplantation
Picture Of The Liver
Image Collection